Generic Name and Formulations:
Sumatriptan (as succinate) 6.5mg/4hrs; iontophoretic transdermal system.
Indications for ZECUITY:
Acute treatment of migraine with or without aura.
Limitations Of use:
Confirm diagnosis; reconsider if no response after treatment. Not for prevention of migraine attacks.
Do not cut transdermal system. Do not apply in areas near or over electrically-active implantable or body-worn medical devices. ≥18yrs: 1 transdermal system applied to the upper arm or thigh only. Max 2 transdermal systems in 24hrs; 2nd system should be applied to a different site no sooner than 2hrs after activation of the 1st system.
<18yrs: not recommended.
Ischemic coronary artery disease (CAD) (eg, angina, history of MI, silent ischemia). Coronary artery vasospasm (including Prinzmetal's angina). Wolff-Parkinson-White syndrome or arrhythmias associated with other cardiac accessory conduction pathway disorders. History of stroke or TIA. History of hemiplegic or basilar migraine. Peripheral vascular disease. Ischemic bowel disease. Uncontrolled hypertension. Within 24hrs of ergot-type drugs (eg, methysergide, dihydroergotamine) or other 5-HT1 agonists. During or within 2 weeks of an MAO-A inhibitor. Severe hepatic impairment. Allergic contact dermatitis to Zecuity.
Avoid excessive use. Remove before MRI procedure. Discontinue if allergic contact dermatitis suspected. Exclude underlying neurologic or cardiovascular disease, supervise 1st dose, and consider monitoring ECG in patients with multiple risk factors (eg, increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD). Monitor BP, cardiovascular function in long-term intermittent use. Discontinue if serious arrhythmias or cerebrovascular events occur or if serotonin syndrome is suspected. Peripheral or GI vascular ischemia and infarction following other 5-HT1 agonists. History, or risk of seizures. Elderly. Pregnancy (Cat.C). Nursing mothers: not recommended.
Ergotamines, other 5-HT1 agonists, MAO-A inhibitors: see Contraindications. Increased risk of serotonin syndrome with SSRIs, SNRIs, tricyclics, or MAO inhibitors.
Selective 5-HT1B/1D receptor agonist.
Application site pain, paresthesia, pruritus, warmth, discomfort, allergic contact dermatitis, chest/throat/neck/jaw discomfort, pressure sensations, medication overuse headache; rare: serious cardiac and cerebrovascular events (including fatalities), vision loss, hypertensive crisis, hypersensitivity reactions.
Single-use transdermal system—4
Psychiatry Advisor Articles
- Anxiety Prevention Interventions: How Effective Are They?
- ADHD, Comorbid Bipolar Disorder Share Similar Neurocognitive Profiles
- Antidepressant Use and Dementia Risk in the Elderly
- Risk for Adverse Outcomes With Antidepressants in Dementia
- Chronic Alcohol Use Disorder Symptoms Occur Regardless of Social Status
- Suicidal Behavior, Thoughts Associated With Perfectionist Tendencies
- CBT, Acceptance Commitment Therapy Helpful for Those With Chronic Pain
- Physicians Spend Nearly 6 Hours on EHR Tasks Per Day
- Depression Reduced by Social Belonging, Feelings of Inclusion
- Sleep Disturbance May Be Causal Factor in Psychotic Experiences
- Buprenorphine, Methadone Combined With CNS Depressants May Lead to SAEs
- Vagus Nerve Stimulation in HIV-Associated Depression
- Depression Profiles in Patients With Type 1 Diabetes vs Type 2 Diabetes
- Purpose, Questions of Social Interaction Lead Physicians to Delay Retirement
- Retirement Saving Behavior Associated With Psychological Distress